logo
Benefits of ADHD medication outweigh health risks, study finds

Benefits of ADHD medication outweigh health risks, study finds

The Guardian06-04-2025

The benefits of taking drugs for attention deficit hyperactivity disorder outweigh the impact of increases in blood pressure and heart rate, according to a new study.
An international team of researchers led by scientists from the University of Southampton found the majority of children taking ADHD medication experienced small increases in blood pressure and pulse rates, but that the drugs had 'overall small effects'. They said the study's findings highlighted the need for 'careful monitoring'.
Prof Samuele Cortese, the senior lead author of the study, from the University of Southampton, said the risks and benefits of taking any medication had to be assessed together, but for ADHD drugs the risk-benefit ratio was 'reassuring'.
'We found an overall small increase in blood pressure and pulse for the majority of children taking ADHD medications,' he said. 'Other studies show clear benefits in terms of reductions in mortality risk and improvement in academic functions, as well as a small increased risk of hypertension, but not other cardiovascular diseases. Overall, the risk-benefit ratio is reassuring for people taking ADHD medications.'
About 3 to 4% of adults and 5% of children in the UK are believed to have ADHD, a neurodevelopmental disorder with symptoms including impulsiveness, disorganisation and difficulty focusing, according to the National Institute for Health and Care Excellence (Nice).
Doctors can prescribe stimulants, such as methylphenidate, of which the best-known brand is Ritalin. Other stimulant medications used to treat ADHD include lisdexamfetamine and dexamfetamine. Non-stimulant drugs include atomoxetine, an sNRI (selective norepinephrine reuptake inhibitor), and guanfacine.
The study of children, adolescents and adults states: 'There is uncertainty regarding whether medications that are used for the treatment of ADHD may lead to cardiovascular diseases, and concerns remain around their cardiovascular safety.' It found all ADHD medications were associated with small increases of blood pressure and heart rate, except guanfacine, which led to decreased blood pressure and heart rate.
There were no significant differences regarding the impact on blood pressure and heart rate between stimulants (including methylphenidate and amphetamine) and non-stimulants (atomoxetine and viloxazine). The researchers advised people with existing heart conditions to discuss the side effects of ADHD medications with a specialist cardiologist before starting treatment.
Dr Ulrich Müller-Sedgwick, a consultant psychiatrist and expert on ADHD, said most clinicians prescribing ADHD medication understood the cardiovascular risks and followed Nice guidelines for monitoring blood pressure, pulse and weight. 'We need more detailed guidelines for scenarios when ADHD medication needs to be adjusted or stopped,' he said.
Last year, a thinktank warned that the NHS was experiencing an 'avalanche of need' over autism and ADHD, and said the system in place to cope with surging demand for assessments and treatments was 'obsolete'. The number of prescriptions issued in England for ADHD medication has risen by 18% year on year since the pandemic, with the biggest rise in London.
Dr Tony Lord, a former chief executive of the ADHD Foundation, said the long-term benefits of ADHD medication were well established, and included a reduced risk of anxiety and depression, eating disorders, harm from smoking, improved educational outcomes and economic independence.
'Sadly ignorance about ADHD medications persists – a throwback to the 80s and 90s when ADHD medications were mistakenly viewed as a morality pill that made naughty, fidgety disruptive children behave – which of course it is not,' he said.
'It is simply a cognitive enhancer that improves information processing, inhibits distractions, improves focus, planning and prioritising, self monitoring and reduces impulsivity of thought and action.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS England to roll out pioneering cancer treatment in world first
NHS England to roll out pioneering cancer treatment in world first

The Independent

time3 hours ago

  • The Independent

NHS England to roll out pioneering cancer treatment in world first

NHS England will be the first health system worldwide to roll out the pioneering "Trojan horse" treatment, belantamab mafodotin (Blenrep), for blood cancer patients. The targeted therapy has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, benefitting approximately 1,500 patients annually. Blenrep, manufactured by GlaxoSmithKline, has been approved by the National Institute for Health and Care Excellence (Nice) for use within the NHS. It will be available to patients whose cancer has advanced or has not responded to initial treatments. Trials suggest that the treatment, in combination with other drugs, delayed disease progression by an average of three years, compared to just over a year for patients taking commonly used drugs.

NHS patients to receive drug that destroys cancer from inside
NHS patients to receive drug that destroys cancer from inside

Telegraph

time4 hours ago

  • Telegraph

NHS patients to receive drug that destroys cancer from inside

A so-called 'Trojan Horse' drug that destroys blood cancer from within is set to be rolled out to thousands of NHS patients. The health service will be the first in the world to make the drug available to patients with multiple myeloma – an incurable cancer of the bone marrow. The drug, called belantamab mafadotin, was developed in the UK and has been dubbed a 'Trojan Horse' therapy because it tricks cancer cells into absorbing it before killing them from within. While the cancer is incurable, treatment is designed to extend people's lives by as much as possible while minimising the impact of side effects and on quality of life. In trials, cancer progression was delayed by three years on average in those taking the drug, which was three times longer than the most common treatment. Around 1,500 patients a year in England will benefit after the treatment was approved by the National Institute for Health and Care Excellence on Thursday. The drug will be offered to patients whose cancer has progressed or not responded to the first choice of treatment using another drug, lenalidomide. Patients who are prescribed the drug will receive it via an infusion once every three weeks in combination with two other cancer treatments.

Blood cancer patients in England first in world to be offered ‘Trojan horse' drug
Blood cancer patients in England first in world to be offered ‘Trojan horse' drug

The Guardian

time4 hours ago

  • The Guardian

Blood cancer patients in England first in world to be offered ‘Trojan horse' drug

Thousands of patients in England with blood cancer will become the first in the world to be offered a pioneering 'Trojan horse' drug that sneaks inside cancer cells and wipes them out. In guidance published on Friday, the National Institute for Health and Care Excellence (Nice) gave the green light to belantamab mafodotin, which can halt the advance of multiple myeloma for three times as long as standard treatments. The targeted therapy, which is given as an infusion every three weeks with other cancer drugs, is a special type of antibody drug that targets and attaches to cancer cells. It has been described as a Trojan horse treatment because it works by being taken into a cancer cell and unleashing a high concentration of a lethal molecule to destroy the cell from inside. Prof Peter Johnson, NHS England's national clinical director for cancer, said the drug would be life-changing for patients and their families. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' he said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.' About 1,500 patients a year in England with multiple myeloma, an incurable cancer of the bone marrow, will benefit from the treatment, also known as Blenrep and made by GlaxoSmithKline. Health officials said the drug would be offered to patients whose cancer had progressed or failed to respond to another first-line treatment. Shelagh McKinlay, the director of research and advocacy at the blood cancer charity Myeloma UK, said it was fantastic to see the NHS become the first healthcare system in the world to roll out the drug. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma,' she said. Paul Silvester, 60, from Sheffield, described the impact of the drug as amazing after he was diagnosed with myeloma in 2023. After the first treatment he received failed to stop his cancer progressing, he was given belantamab mafodotin through an early access programme at the Royal Hallamshire hospital. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. Trials suggest the treatment, in combination with bortezomib and dexamethasone, delays progression of the disease by an average of three years, compared with one year for patients taking the commonly used drug daratumumab along with the other treatments. Helen Knight, the director of medicines evaluation at Nice, said: 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' The health minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge 'Trojan horse' technology, we're offering new hope to blood cancer patients across the country.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store